Plus Therapeutics Inc (PSTV) Stock Price, Quote & News

Company Profile

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat va...

Industry: Biotechnology

Sector: Healthcare

Phone: 737 255 7194

Fax: 210 974 6901

Website: plustherapeutics.com

Address:

6420 LEVIT GREEN BOULEVARD, SUITE 210, Houston, United States

zzzzzzzzzzzxxx May. 13 at 12:51 AM

$PSTV

0 · Reply

zzzzzzzzzzzxxx May. 13 at 12:50 AM

$PSTV

0 · Reply

Love_To_Learn May. 13 at 12:25 AM

$PSTV $SLS !

2 · Reply

Love_To_Learn May. 13 at 12:25 AM

$PSTV $SLS ! ENJOY YOUR EVENING!

2 · Reply

Vulnerable May. 12 at 11:17 PM

$PSTV very impressive how he can drive a stock like $WOK with a 4.8 million market cap up. @Love_To_Learn wasn't posting about wok for months (years) on end but certainly pumping on way up to catch some fish and play the ride back down. VERY IMPRESSIVE YOU PUMPED IT TO $10 considering iT WAS ONLY 8,000.00 a share last year.

1 · Reply

Vulnerable May. 12 at 10:57 PM

$PSTV I'm getting excited the last 1000 time you posted like this 99% of the stocks you tagged went down 99%. Best case, dilution announced, next best case you blame the board or marc and price drops. worse case scenario, delay or nothing happens. Shorts thank you MO. You are the best and most consistent shorter I've ever found. I did like a few pops to short on other tickers and got a LOL out of you pulling SLS all the back to where you shorted it from 5 yrs ago - looks like a good point for a pull back.

0 · Reply

Love_To_Learn May. 12 at 10:20 PM

$PSTV NANO PARTICLE NEXT PHASE IS READY FOR MARKETS NOW FOR PANDORA FRIDAY ! SETTING UP PANDORA FRIDAY NOW FOR WORLD GLOBAL RAMIFICATIONS

0 · Reply

Love_To_Learn May. 12 at 10:07 PM

$WOK CODING THIS 6.52 MAKING THE COUNTDOWN TIMER FASTER NOW 1.25 COMPRESSION ON THE COUNTDOWN 4 MARKETS $SLS $PSTV ACTIVATING NANO PARTICLE AND OUR SPECIAL ABILITY ON BELOVED DEATH TOUCH FOR MARKET MOVERS ENTIRE MARKET WIDE SENDING MESSAGE TO U THATS A GO DON U HAVE THE GREEN LIGHT * PROCEED * XI JINPING SEND YOUR TEAM NOW *

0 · Reply

Love_To_Learn May. 12 at 10:05 PM

$PSTV NO VASELINE BENDING U OVER !

0 · Reply

Love_To_Learn May. 12 at 10:04 PM

$PSTV HOPE U READY SHORTS !

0 · Reply

Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases

May 7, 2026, 7:30 AM EDT - 6 days ago

Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic

Apr 28, 2026, 7:30 AM EDT - 15 days ago

Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Apr 23, 2026, 7:30 AM EDT - 20 days ago

Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™

Apr 22, 2026, 4:30 PM EDT - 20 days ago

Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

2026-04-21T11:59:57.000Z - 22 days ago

Plus Therapeutics regains compliance with Nasdaq minimum bid price requirement

Apr 21, 2026, 7:30 AM EDT - 22 days ago

Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 15, 2026, 7:30 AM EDT - 4 weeks ago

Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution

2026-04-09T11:57:58.000Z - 4 weeks ago

Plus Therapeutics appoints Eric Daniels as chief development officer

Apr 9, 2026, 7:30 AM EDT - 4 weeks ago

Plus Therapeutics Appoints Eric J. Daniels, M.D.

2026-04-08T11:39:50.000Z - 5 weeks ago

Plus Therapeutics granted Orphan Drug Designation for Reyobiq

Apr 8, 2026, 7:30 AM EDT - 5 weeks ago

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas

2026-04-07T15:15:27.000Z - 5 weeks ago

Plus Therapeutics price target lowered to $12 from $37.50 at Maxim

2026-04-07T11:55:34.000Z - 5 weeks ago

Plus CNSide Cerebrospinal Fluid Tumor Cell Enumeration test gets AMA PLA code

Apr 7, 2026, 7:30 AM EDT - 5 weeks ago

Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption

2026-04-06T22:20:10.000Z - 5 weeks ago

Plus Therapeutics’ treatment of malignant glioma granted FDA orphan designation

Apr 2, 2026, 7:30 AM EDT - 5 weeks ago

Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives

2026-04-01T23:50:16.000Z - 5 weeks ago

Plus Therapeutics Inc (USA) trading halted, news pending

2026-03-31T14:45:55.000Z - 6 weeks ago

Plus Therapeutics downgraded to Hold from Buy at D. Boral Capital

2026-03-31T11:38:10.000Z - 6 weeks ago

Plus Therapeutics announces 1-for-25 reverse stock split

Mar 26, 2026, 7:30 AM EDT - 6 weeks ago

Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors

2026-03-19T12:01:47.000Z - 7 weeks ago

Plus Therapeutics’ CNSide assay may reduce healthcare costs

Mar 19, 2026, 7:30 AM EDT - 7 weeks ago

Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%

2026-03-12T21:05:16.000Z - 2 months ago

Plus Therapeutics reports Q4 EPS (29c), consensus (4c)

Mar 12, 2026, 4:15 PM EDT - 2 months ago

Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

2026-02-25T12:39:49.000Z - 2 months ago

Plus announces new Category III CPT code for CED used with Reyobiq

Feb 25, 2026, 7:30 AM EST - 2 months ago

Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™

2026-02-03T13:40:32.000Z - 3 months ago

Plus Therapeutics initiated with a Buy at Lake Street

2026-01-23T15:00:32.000Z - 3 months ago

Plus Therapeutics price target lowered to $1.50 from $3 at Maxim

2026-01-23T11:11:22.000Z - 3 months ago

Plus Therapeutics price target lowered to $1 from $2 at H.C. Wainwright

Jan 22, 2026, 9:00 AM EST - 3 months ago

Plus Therapeutics Transcript: Business update

2026-01-22T12:50:20.000Z - 3 months ago

Plus Therapeutics announces anticipated milestones for FY26

Jan 21, 2026, 4:15 PM EST - 3 months ago

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

2026-01-14T13:17:53.000Z - 4 months ago

Plus Therapeutics prices 39.5M units at 38c in upsized public offering

Jan 14, 2026, 8:00 AM EST - 4 months ago

Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering

2026-01-09T21:15:15.000Z - 4 months ago

Plus Therapeutics files to sell 22.32M units

2026-01-08T12:36:17.000Z - 4 months ago

Plus announces completion of Type B meeting with U.S. FDA for REYOBIQ

Jan 8, 2026, 7:30 AM EST - 4 months ago

Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases

2025-12-11T12:40:58.000Z - 5 months ago

Plus Therapeutics expands CNSide assay platform to State of California

Dec 11, 2025, 7:30 AM EST - 5 months ago

Plus Therapeutics Expands CNSide Assay Platform to State of California

Dec 9, 2025, 7:30 AM EST - 5 months ago

Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants

Dec 4, 2025, 7:30 AM EST - 5 months ago

Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting

Dec 1, 2025, 7:30 AM EST - 5 months ago

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium

Nov 24, 2025, 7:30 AM EST - 6 months ago

Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases

Nov 20, 2025, 7:30 AM EST - 6 months ago

Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Nov 17, 2025, 7:30 AM EST - 6 months ago

Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Nov 6, 2025, 7:30 AM EST - 6 months ago

Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

Oct 30, 2025, 4:15 PM EDT - 6 months ago

Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights

Oct 21, 2025, 7:30 AM EDT - 7 months ago

Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch

Sep 25, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Sep 22, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT

Sep 18, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory

Sep 2, 2025, 4:15 PM EDT - 9 months ago

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria

Aug 18, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

Aug 15, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

Aug 14, 2025, 4:15 PM EDT - 9 months ago

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

Aug 14, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference

Jul 31, 2025, 7:30 AM EDT - 10 months ago

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

Jul 23, 2025, 7:30 AM EDT - 10 months ago

Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT

Jul 15, 2025, 7:30 AM EDT - 10 months ago

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases

Jul 10, 2025, 7:30 AM EDT - 10 months ago

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference

Jul 8, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jun 30, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jun 26, 2025, 9:00 AM EDT - 11 months ago

Plus Therapeutics Transcript: Business Update

Jun 26, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

Jun 25, 2025, 4:15 PM EDT - 11 months ago

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET

Jun 25, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer

Jun 24, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing

May 30, 2025, 4:15 PM EDT - 1 year ago

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

May 23, 2025, 4:15 PM EDT - 1 year ago

Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

May 14, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)

zzzzzzzzzzzxxx May. 13 at 12:51 AM

$PSTV

0 · Reply

zzzzzzzzzzzxxx May. 13 at 12:50 AM

$PSTV

0 · Reply

Love_To_Learn May. 13 at 12:25 AM

$PSTV $SLS !

2 · Reply

Love_To_Learn May. 13 at 12:25 AM

$PSTV $SLS ! ENJOY YOUR EVENING!

2 · Reply

Vulnerable May. 12 at 11:17 PM

1 · Reply

Vulnerable May. 12 at 10:57 PM

0 · Reply

Love_To_Learn May. 12 at 10:20 PM

$PSTV NANO PARTICLE NEXT PHASE IS READY FOR MARKETS NOW FOR PANDORA FRIDAY ! SETTING UP PANDORA FRIDAY NOW FOR WORLD GLOBAL RAMIFICATIONS

0 · Reply

Love_To_Learn May. 12 at 10:07 PM

0 · Reply

Love_To_Learn May. 12 at 10:05 PM

$PSTV NO VASELINE BENDING U OVER !

0 · Reply

Love_To_Learn May. 12 at 10:04 PM

$PSTV HOPE U READY SHORTS !

0 · Reply

zamin_1989 May. 12 at 9:17 PM

$PSTV What the hell hit you in the head again? Just die already — why are you struggling so much to stay alive?

0 · Reply

Love_To_Learn May. 12 at 9:08 PM

$PSTV soon mr hedrick

0 · Reply

Investor1862 May. 12 at 6:20 PM

$PSTV back below 1 soon

0 · Reply

zzzzzzzzzzzxxx May. 12 at 5:30 PM

$PSTV here we gooooo

0 · Reply

Love_To_Learn May. 12 at 5:18 PM

$PSTV WILL TAKE OVER BOTH UPDATES DUE TO MARKET CONDITIONS AT THIS TIME $SLS * !

0 · Reply

Love_To_Learn May. 12 at 5:17 PM

$PSTV SECURING FLOORS $SLS NEED TO SHIFT 498 MILLION SHARES AROUND * RE COORDINATING WITH U ANGELOS CHANGING MARKET DYNAMIC TIMING THIS WED-FRI TIMER

1 · Reply

Love_To_Learn May. 12 at 5:12 PM

$PSTV SHIFTING 250 MILLION SYNTHETIC SHARES TO TRANSFER OUT

0 · Reply

Love_To_Learn May. 12 at 5:11 PM

$PSTV HOLD OFF AT THIS MOMENT MARC WAIT FOR MARKET CONDITIONS SHIFTING MARKET FOR U NOW COORDINATING WITH U OK !

1 · Reply

zzzzzzzzzzzxxx May. 12 at 4:53 PM

$PSTV intact

0 · Reply

zzzzzzzzzzzxxx May. 12 at 4:23 PM

$PSTV normal before the megapump

0 · Reply

zzzzzzzzzzzxxx May. 12 at 2:50 PM

$PSTV red IS goooood tomo green

0 · Reply

zzzzzzzzzzzxxx May. 12 at 2:35 PM

$PSTV be patient news tomo

0 · Reply

Market Cap	41.45M
Revenue (ttm)	5.21M
Net Income (ttm)	-22.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-429.75%
Debt to Equity Ratio	0.19

Volume	92,500
Avg Vol	348,989
Day's Range	N/A - N/A
Shares Out	6.86M
Stochastic %K	30%
Beta	1.40
Analysts	Sell
Price Target	$38.50